VATS vs. open lobectomy for early stage non-small cell lung cancer

Shawn S. Groth, Michael A Maddaus

Research output: Chapter in Book/Report/Conference proceedingChapter


Of the estimated 219,440 people in the United States who will be diagnosed with lung cancer in 2009,1 about 13% (32,900 people) will have early stage (American Joint Committee on Cancer [AJCC] stage I and II) non-small cell lung cancer (NSCLC).2,3 Patients with untreated stage I NSCLC, albeit an early stage neoplasm, have a 5-year survival rate of less than 5%. 4 - 6 Radiation and chemotherapy (alone or in combination) offer little survival benefit. Only patients who undergo complete surgical resection are afforded a significant chance at long-term survival.7-9 Because early stage tumors are confined within a focus of lung parenchyma, the goal of pulmonary resection for early stage NSCLC is to obtain local control of the tumor, thereby preventing future tumor dissemination. The current standard of care for treating early stage NSCLC patients with sufficient cardiopulmonary reserve is a lobectomy10,11 and complete mediastinal lymph node dissection.12,13

Original languageEnglish (US)
Title of host publicationDifficult Decisions in Thoracic Surgery (Second Edition)
Subtitle of host publicationAn Evidence-Based Approach
PublisherSpringer London
Number of pages12
ISBN (Print)9781849963640
StatePublished - Dec 1 2011


Dive into the research topics of 'VATS vs. open lobectomy for early stage non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this